Nomura Upgrades Johnson Pharmaceuticals' Target Price by 2% to HK$18.36, Maintains Neutral Rating

Jinshi data news on February 26th, Nomura released a report, raising the target price of Johnson Pharmaceuticals (03692.HK) by 2% to 18.36 Hong Kong dollars from 17.95 Hong Kong dollars, reflecting a downside of 3.2%, maintaining a neutral rating. The bank expects a 0.5% decline in revenue in the second half of 2024, and profits to decrease by 35% annually. The bank has lowered its revenue and profit forecasts for the 2024 fiscal year by 0.6% and 4.2%, respectively, and raised its revenue and profit forecasts for the 2025 fiscal year by 4.5% and 1.8%, factors considered include the cooperation revenue from authorizing HS-10535 (oral GLP-1 asset) to MSD, and sales performance exceeding expectations.

View Original
This page may contain third-party content, which is provided for information purposes only (not representations/warranties) and should not be considered as an endorsement of its views by Gate, nor as financial or professional advice. See Disclaimer for details.
  • Reward
  • Comment
  • Repost
  • Share
Comment
0/400
No comments
Trade Crypto Anywhere Anytime
qrCode
Scan to download Gate App
Community
English
  • 简体中文
  • English
  • Tiếng Việt
  • 繁體中文
  • Español
  • Русский
  • Français (Afrique)
  • Português (Portugal)
  • Bahasa Indonesia
  • 日本語
  • بالعربية
  • Українська
  • Português (Brasil)